Comparative Pharmacology
Head-to-head clinical analysis: BROMPHENIRAMINE MALEATE versus CORSYM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROMPHENIRAMINE MALEATE versus CORSYM.
BROMPHENIRAMINE MALEATE vs CORSYM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of histamine at H1 receptor sites, suppressing histamine-induced vasodilation, increased capillary permeability, and bronchoconstriction.
Phenylephrine is a selective α1-adrenergic receptor agonist causing vasoconstriction; chlorpheniramine is a first-generation antihistamine that competitively inhibits histamine at H1 receptors.
4 mg orally every 4-6 hours, not to exceed 24 mg/day. Alternatively, extended-release: 12 mg every 12 hours.
Adults: 100 mg orally once daily, taken with water at least 1 hour before meals. Maximum dose 100 mg/day.
None Documented
None Documented
Terminal half-life 22-25 hours; prolonged in hepatic impairment or elderly (up to 40 hours).
The terminal elimination half-life for hydrocodone from the CORSYM formulation is approximately 8-10 hours, reflecting the extended-release profile. This allows for twice-daily dosing. Hydrocodone's half-life in immediate-release forms is about 3-4 hours, so the polistirex complex prolongs absorption. Chlorpheniramine has a half-life of about 20-24 hours in adults, but in the polistirex formulation, its half-life is extended to approximately 18-22 hours, supporting once-daily dosing for the antihistamine component.
Renal (85-90% as metabolites, 5-10% unchanged); biliary/fecal <5%.
CORSYM (hydrocodone polistirex and chlorpheniramine polistirex) is an extended-release formulation. Hydrocodone is metabolized primarily in the liver via CYP3A4 and CYP2D6 to norhydrocodone, hydromorphone, and other metabolites. Excretion is predominantly renal (about 90%) as unchanged drug and metabolites, with approximately 10% excreted in feces via biliary elimination. Chlorpheniramine is metabolized in the liver and excreted renally as metabolites (about 70-80%) and unchanged drug (about 10-20%), with minor fecal excretion.
Category C
Category C
Antihistamine
Antihistamine/Decongestant